Genetic Variability in Cisplatin Metabolism in Kidney Injury in Patients With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Chemoradiotherapy.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 40342074.
- Also identified by DOI 10.1002/hed.28179 and PMC identifier 12434574.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This study investigated the roles of single nucleotide variants (SNVs) in genes of CDDP metabolism and their association with kidney dysfunction in patients with head and neck squamous cell carcinoma (HNSCC). A total of 109 patients with locally advanced HNSCC, treated with CDDP, had renal function evaluated by serum creatinine level and CKD-EPI formula, and underwent genotyping by polymerase chain reaction. Patients with GSTT1 present and ERCC1 c.354CT or TT genotypes showed 4.94% and 8.94% renal function reduction, respectively. GSTT1 present with TP53 c.215G>C (17.67%), GSTP1 c.313A>G with ERCC1 c.354C>T (17.57%), GSTP1 c.313A>G with MLH1 c.93G>A (12.49%), GSTP1 c.313A>G with MSH3 c.3133A>G (12.19%), ERCC1 c.354C>T with MLH1 c.93G>A (18.85%) and ERCC1 c.354C>T with MSH3 c.3133A>G (13.38%) combined genotypes were also associated with substantial declines in renal function. Our data suggest that isolated and combined SNVs in genes enrolled in CDDP metabolism can be used to select patients for treatments that spare the kidneys from adverse effects.
Medical subject headings
- Cisplatin
- Chemoradiotherapy
- Head and Neck Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Antineoplastic Agents
- Acute Kidney Injury